ArticleFrontiers in immunology2026
Comparing CD8+ T cell ENV epitopes of two HLA class I alleles associated with different outcomes of HIV-1 infection with broadly neutralizing antibodies epitope targets discovered to date.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The HIV vaccine field has swung between humoral-based to cell-mediated approaches; however the consensus has evolved toward the understanding that an induction of both may be important for optimal protection. HLA class I molecules present viral epitopes to initiate CD8+ T cell responses to HIV-infected cells while broadly neutralizing antibodies (bNAbs) primarily target free virions. In this study, we systematically compared HIV-1 ENV CD8+ T cell epitopes restricted by two HLA class I alleles associated with divergent HIV-1 infection outcomes with bNAb epitopes reported to date in the literature. To our knowledge, this represents one of the first attempts of examining and reconciling the targets of cellular and humoral immunity in the context of differing HIV infection outcomes. Among 1820 peptides overlapping HIV-1 clades A and D ENV, A*01:01 (associated with slower HIV-1 acquisition) bound to 20, while B*07:02 (associated with susceptibility) bound to 64. No significant differences in affinity or off-rate were noted between A*01:01 and B*07:02 epitopes, and a higher proportion of A*01:01 epitopes are located within constant ENV regions than B*07:02 epitopes (C:V ratio 3:1 versus 2:1, respectively). Of the epitopes and variants discovered in this study, 7 of 20 (35%) A*01:01 and 11 of 64 (17%) B*07:02 binders overlapped with known bNAb target sites. All CD8+ T cell epitopes overlapping CD4-binding site clusters were also bNAbs targets. Notably, all A*01:01 T cell epitopes overlapping bNAb epitopes were within conserved ENV regions, and all but one involved glycan-dependent bNAb binding. The epitope landscape analysis therefore showed the allele associated with slower HIV-1 infection rates presents a narrower repertoire of ENV CD8
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.